Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Quintela-Fandino M, et al. Among authors: tsao m. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2. Mol Cancer Ther. 2010. PMID: 20197396 Free PMC article. Clinical Trial.
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Renouf DJ, Tang PA, Hedley D, Chen E, Kamel-Reid S, Tsao MS, Tran-Thanh D, Gill S, Dhani N, Au HJ, Wang L, Moore MJ. Renouf DJ, et al. Among authors: tsao ms. Eur J Cancer. 2014 Jul;50(11):1909-15. doi: 10.1016/j.ejca.2014.04.008. Epub 2014 May 21. Eur J Cancer. 2014. PMID: 24857345 Clinical Trial.
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS. da Cunha Santos G, et al. Cancer. 2010 Dec 15;116(24):5599-607. doi: 10.1002/cncr.25393. Epub 2010 Sep 7. Cancer. 2010. PMID: 20824720 Free article. Clinical Trial.
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
Sacher AG, Le LW, Lara-Guerra H, Waddell TK, Sakashita S, Chen Z, Kim L, Zhang T, Kamel-Reid S, Salvarrey A, Darling G, Yasufuku K, Keshavjee S, de Perrot M, Shepherd FA, Liu G, Tsao MS, Leighl NB. Sacher AG, et al. Among authors: tsao ms. Oncotarget. 2016 May 3;7(18):25632-9. doi: 10.18632/oncotarget.8350. Oncotarget. 2016. PMID: 27028852 Free PMC article. Clinical Trial.
Minimalist approaches to cancer tissue-of-origin classification by DNA methylation.
Xia D, Leon AJ, Cabanero M, Pugh TJ, Tsao MS, Rath P, Siu LL, Yu C, Bedard PL, Shepherd FA, Zadeh G, Chetty R, Aldape K. Xia D, et al. Among authors: tsao ms. Mod Pathol. 2020 Oct;33(10):1874-1888. doi: 10.1038/s41379-020-0547-7. Epub 2020 May 15. Mod Pathol. 2020. PMID: 32415265 Free PMC article.
1,104 results